ATTACHMENT B_COSMOS Eligibility and Conformance Certification Sheet.docx
DOCX document 36 KB Posted
- Attached to
- ARPA-H Comprehensive Organ System Modeling in Outer Space (COSMOS) Innovative Solutions Opening
- Solicitation number
- ARPA-H-SOL-26-165
About this file
This is an Eligibility and Conformance Certification Sheet for the ARPA-H COSMOS (Comprehensive Organ System Modeling in Outer Space) Innovative Solutions Opening (ARPA-H-SOL-26-165). The document serves as a checklist template for prospective bidders to certify their proposal compliance with specific technical and programmatic requirements.
Proposers must verify that 75% of experimental samples utilize microphysiological systems (MPS) for Phases I and II, address donor heterogeneity requirements through dedicated planning and budgeting, and select a single organ system from heart, brain, uterus, kidney, or other. The certification requires documentation of planned -omics approaches for validating Phase I experiments and confirmation of technical capacity to create and maintain up to 384 MPS units simultaneously, with 192 designated for spaceflight in the Low Earth Orbit (LEO) twin experiment. Proposals must incorporate specific biomarker and modeling components, including two tissue-agnostic and two tissue-specific biomarkers of aging, at least two age-related biological pathways, biomarkers of tissue integrity, and an optically clear chip design. Additionally, proposers must describe in silico modeling based on extant aging data for their selected organ, integration of terrestrial data into the TAROE alpha or TARIS alpha model, and final variance analysis between LEO-flown and terrestrial control cells. The sheet also requires confirmation that proposals identify a prospective list of biopharma partners relevant to the selected tissue type. This template applies to the Department of Health and Human Services National Institutes of Health solicitation for multiple Other Transaction awards.
View the file
Other files
| File | Type | Posted |
|---|---|---|
| ARPA-H-SOL-26-165_COSMOS_QA_Set_2_2026-09-25.pdf | ||
| ARPA-H-SOL-26-165_COSMOS_ISO_Amendment 02.pdf | ||
| ARPA-H-SOL-26-165_COSMOS_QA_Set_1_2026-09-21.pdf | ||
| ARPA-H-SOL-26-165_COSMOS_ISO_Amendment 01.pdf | ||
| Attachment E_COSMOS Administrative and National Policy Requirements.docx | DOCX document | |
| Attachment D_COSMOS Cost Proposal Template.xlsx | XLSX spreadsheet | |
| ATTACHMENT A.2_Task Description Document Model.docx | DOCX document | |
| ATTACHMENT C COSMOS Schedule.xlsx | XLSX spreadsheet | |
| ATTACHMENT A.1_Technical & Management Proposal Model (VOL I).docx | DOCX document | |
| ATTACHMENT A.3_COSMOS Milestone and Payment Table.xlsx | XLSX spreadsheet | |
| ARPA-H-SOL-26-165_COSMOS_ISO.docx | DOCX document |
Show all 11
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
Attachment B: Eligibility and Conformance Certification Sheet Prime/Submitting Entity Name:
Prime/Submitting Entity's Unique Entity Identification (UEI):
Names of ALL subperformer institutions, entities, and/or companies:
| Are ≥75% of the experimental samples for Phases I and II microphysiological systems (MPS)? |
| Choose an item. |
| Have you proposed a plan and budget to meet the Donor Heterogeneity Requirements? |
| Choose an item. |
Which single organ does your proposal target?
Check all that apply ☐Heart ☐Brain ☐Uterus ☐Kidney ☐Other:
| List the planned -omics approaches being proposed to assess and validate Phase I experiments? |
| ☐1: (Describe) |
☐2: (Describe) ☐3: (Describe) ☐4: (Describe)
| Does your technical approach include a plan for creating and simultaneously maintaining up to 384 MPS (all in autonomous housings, 192 for spaceflight) for the LEO twin experiment? |
| Choose an item. |
| Your technical approach for MPS monitoring includes (check all that apply): |
| ☐ ≥ 2 tissue-agnostic biomarkers of aging |
☐ ≥ 2 tissue-specific biomarkers of aging ☐ ≥ 2 age-related biological pathways (e.g., stress, senescence, inflammation) ☐ tissue agnostic and tissue specific biomarkers of tissue integrity ☐ an optically clear chip design
| Your modeling includes (check all that apply): |
| ☐ Description of in silico model based on extant data regarding aging in the specific organ of interest |
☐ Plan to integrate data gathered from Terrestrial Arm into the TAROE alpha model ☐TARIS alpha model approach ☐ Final analysis of any variance between LEO-flown cells and terrestrial twins
| Does your proposal address the requirement for a prospective list of biopharma partners relevant to your selected tissue? |
| Choose an item. |
File details come from the government source that posted it. Updated .